Dyadic International, Inc. applauded the signing of an agreement between Dyadic?s African licensee, Rubic One Health and Afreximaxbank to fund the project preparatory facility for the manufacture of vaccines using Dyadic?s C1 protein production platform in South Africa for the entire continent. In April 2023, Dyadic expanded its licensing agreement with Rubic, whose mission is to develop African-based solutions for the discovery, development, evaluation and manufacture of high-quality, cost-effective human and animal vaccines and therapeutic proteins using Dyadic?s C1 expression platform for distribution primarily to the African market. The quest to produce affordable vaccines suited to humans and animals in Africa has taken a step closer to realization with the signing of the agreement between Rubic and Afreximaxbank.